Press Releases

November 3, 2017

Regulatory

Interim report Q3 2017

October 6, 2017

Regulatory

CEO, CFO and CSO increase their shareholdings in SynAct

October 3, 2017

Regulatory

The first part of the clinical Phase I study with SynAct Pharma’s drug candidate AP1189 successfully completed

August 31, 2017

Regulatory

Half-yearly report 01-01-2017 – 30-06-2017

June 7, 2017

Regulatory

SynAct Pharma announces the start of Clinical Phase I study

May 11, 2017

Regulatory

Bulletin from the Annual General Meeting of SynAct Pharma AB (publ)

May 11, 2017

Regulatory

Interim report Q1 2017   Synact Pharma

May 10, 2017

Regulatory

SynAct Pharma AB receives approval to start Clinical Phase I study with AP1189 – a new potential treatment for psoriatic arthritis

April 27, 2017

Regulatory

Utilisation of subscription options registered with Swedish Companies Registration Office

April 25, 2017

Regulatory

SynAct Pharma AB provides an update on the clinical development plan for AP1189

April 20, 2017

Regulatory

Annual Report 2016

April 11, 2017

Regulatory

Notice of Annual General Meeting of SynAct Pharma AB (publ)

March 31, 2017

Regulatory

SynAct Pharma AB will raise 1,007,539.20 SEK through the utilisation of series TO 1 subscription options

March 17, 2017

Regulatory

Reminder of the utilisation of series TO 1 subscription options

March 9, 2017

Regulatory

SynAct Pharma AB retains subscription rights for series TO 1subscription option

March 9, 2017

Regulatory

The utilisation period of SynAct Pharma AB’s series TO 1 subscription options starts today

February 22, 2017

Regulatory

SynAct Pharma AB has received approval from the Ethics Committee and continues its dialogue with the French Medicines Agency

February 9, 2017

Regulatory

SynAct Pharma Year-end report 2016

January 27, 2017

SynAct presented in Copenhagen at Sedermera Investor Event